CAPLIN POINT LABORATORIES Financial Statement Analysis
|
||
|
The Revenues of CAPLIN POINT LABORATORIES have increased by 15.54% YoY .
The Earnings Per Share (EPS) of CAPLIN POINT LABORATORIES has increased by 21.40 % YoY. |
||
| REVENUES |
| OPERATING MARGIN |
| PROFIT AFTER TAX |
| EPS |
| ROCE |
CAPLIN POINT LABORATORIES Last 5 Annual Financial Results
[BOM: 524742|NSE : CAPLIPOINT]
| Consolidated | Mar2024 | Mar2023 | Mar2022 | Mar2021 | Mar2020 |
|---|---|---|---|---|---|
| Revenues | ₹1,467 Cr | ₹1,269 Cr | ₹1,061 Cr | ₹86,320 Cr | ₹649 Cr |
| Expenses | ₹1,026 Cr | ₹875 Cr | ₹737 Cr | ₹60,313 Cr | ₹417 Cr |
| Operating Profit (Excl OI) | ₹441 Cr | ₹395 Cr | ₹324 Cr | ₹26,007 Cr | ₹232 Cr |
| Other Income | ₹57 Cr | ₹39 Cr | ₹28 Cr | ₹4,133 Cr | ₹19 Cr |
| Interest | ₹0.78 Cr | ₹0.70 Cr | ₹1.59 Cr | ₹32 Cr | ₹0.58 Cr |
| Depreciation | ₹45 Cr | ₹47 Cr | ₹37 Cr | ₹3,162 Cr | ₹23 Cr |
| Profit Before Tax | ₹451 Cr | ₹386 Cr | ₹314 Cr | ₹26,946 Cr | ₹227 Cr |
| Profit After Tax | ₹377 Cr | ₹308 Cr | ₹251 Cr | ₹21,508 Cr | ₹177 Cr |
| Consolidated Net Profit | ₹376 Cr | ₹300 Cr | ₹242 Cr | ₹21,501 Cr | ₹177 Cr |
| Earnings Per Share (Rs) | ₹60.18 | ₹49.57 | ₹39.56 | ₹32.03 | ₹28.42 |
| PAT Margin (%) | 27.24 | 25.70 | 24.30 | 23.69 | 24.92 |
| ROE(%) | 22.97 | 23.68 | 24.77 | 25.65 | 29.58 |
| ROCE(%) | 26.92 | 26.85 | 28.77 | 28.82 | 33.35 |
| Total Debt/Equity(x) | 0.00 | 0.00 | 0.00 | 0.01 | 0.04 |
Key Financials |
||
| Market Cap | : | ₹ 14,212.8 Cr |
| Revenue (TTM) | : | ₹ 1,757.7 Cr |
| Net Profit(TTM) | : | ₹ 481.9 Cr |
| EPS (TTM) | : | ₹ 63.4 |
| P/E (TTM) | : | 29.5 |
| Industry Peers & Returns | 1W | 1M | 1Y |
| CAPLIN POINT LABORATORIES | -2% | -6.7% | 72.6% |
| SUN PHARMACEUTICAL INDUSTRIES | -0.6% | 1.3% | 65.7% |
| CIPLA | -2.3% | -6.8% | 33.8% |
| DR REDDYS LABORATORIES | 1.5% | 1% | 22.9% |
| ZYDUS LIFESCIENCES | -4.2% | -8.1% | 72.3% |
| DIVIS LABORATORIES | -1.1% | 11.4% | 64% |
| MANKIND PHARMA | -4% | 9.3% | 51.6% |
| TORRENT PHARMACEUTICALS | -2.9% | -1.6% | 85.6% |
| LUPIN | -2.1% | -4.1% | 84.5% |
CAPLIN POINT LABORATORIES Revenues
[BOM: 524742|NSE : CAPLIPOINT]
| Y-o-Y | 15.54 % |
| 5 Yr CAGR | 22.62 % |
| Years | Revenues | % Change | |
|---|---|---|---|
| Mar2024 | ₹1,467 Cr | 15.54 | |
| Mar2023 | ₹1,269 Cr | 19.61 | |
| Mar2022 | ₹1,061 Cr | -98.77 | |
| Mar2021 | ₹86,320 Cr | 13,206.82 | |
| Mar2020 | ₹649 Cr | - | |
CAPLIN POINT LABORATORIES Operating Profit
[BOM: 524742|NSE : CAPLIPOINT]
| Y-o-Y | 11.66 % |
| 5 Yr CAGR | 17.41 % |
| Years | Operating Profit | % Change | |
|---|---|---|---|
| Mar2024 | ₹441 Cr | 11.66 | |
| Mar2023 | ₹395 Cr | 21.67 | |
| Mar2022 | ₹324 Cr | -98.75 | |
| Mar2021 | ₹26,007 Cr | 11,116.87 | |
| Mar2020 | ₹232 Cr | - | |
| Operating Margins | |
|---|---|
| Y-o-Y | -3.38 % |
| 5 Yr CAGR | -4.26 % |
| Years | Operating Margin% | % Change | |
|---|---|---|---|
| Mar2024 | 30.03% | -3.38 | |
| Mar2023 | 31.08% | 1.73 | |
| Mar2022 | 30.55% | 1.39 | |
| Mar2021 | 30.13% | -15.70 | |
| Mar2020 | 35.74% | - | |
CAPLIN POINT LABORATORIES Profit After Tax
[BOM: 524742|NSE : CAPLIPOINT]
| Y-o-Y | 25.49 % |
| 5 Yr CAGR | 20.82 % |
| Years | Profit After Tax | % Change | |
|---|---|---|---|
| Mar2024 | ₹376 Cr | 25.49 | |
| Mar2023 | ₹300 Cr | 23.76 | |
| Mar2022 | ₹242 Cr | -98.87 | |
| Mar2021 | ₹21,501 Cr | 12,077.96 | |
| Mar2020 | ₹177 Cr | - | |
| PAT Margins | |
|---|---|
| Y-o-Y | 5.99 % |
| 5 Yr CAGR | 2.25 % |
| Years | PAT Margin(%) | % Change | |
|---|---|---|---|
| Mar2024 | 27.24 % | 5.99 | |
| Mar2023 | 25.7 % | 5.76 | |
| Mar2022 | 24.3 % | 2.57 | |
| Mar2021 | 23.69 % | -4.94 | |
| Mar2020 | 24.92 % | - | |
CAPLIN POINT LABORATORIES Earnings Per Share (EPS)
[BOM: 524742|NSE : CAPLIPOINT]
| Y-o-Y | 21.40 % |
| 5 Yr CAGR | 20.63 % |
| Years | EPS | % Change | |
|---|---|---|---|
| Mar2024 | ₹60 | 21.40 | |
| Mar2023 | ₹50 | 25.30 | |
| Mar2022 | ₹40 | 23.51 | |
| Mar2021 | ₹32 | 12.70 | |
| Mar2020 | ₹28 | - | |
CAPLIN POINT LABORATORIES Return on Capital Employed (ROCE)
[BOM: 524742|NSE : CAPLIPOINT]
| Y-o-Y | 0.26 % |
| 5 Yr CAGR | -5.21 % |
| Years | ROCE | % Change | |
|---|---|---|---|
| Mar2024 | 26.92% | 0.26 | |
| Mar2023 | 26.85% | -6.67 | |
| Mar2022 | 28.77% | -0.17 | |
| Mar2021 | 28.82% | -13.58 | |
| Mar2020 | 33.35% | - | |
CAPLIN POINT LABORATORIES Share Price vs Sensex
| Current Share Price | : | ₹1,870.1 |
| Current MarketCap | : | ₹ 14,212.8 Cr |
| Updated EOD on | : | Oct 17,2024 |
| Share Price Returns(%) | 1 Week | 1 Month | 1 Year |
| CAPLIN POINT LABORATORIES | -2% |
-6.7% |
72.6% |
| SENSEX | -0.7% |
-2.4% |
22% |
CAPLIN POINT LABORATORIES related INDICES
| BSE Indices | 1W | 1M | 1Y |
|---|---|---|---|
| S&P BSE SMALL CAP | 0.4% | -1.2% | 48.1% |
| S&P BSE 250 SMALLCAP | 0.4% | -1.7% | 44.8% |
| S&P BSE HEALTHCARE | 0.2% | -0.5% | 56.5% |
| S&P BSE MIDSMALLCAP | -0.2% | -2% | 48.1% |
| S&P BSE 400 MIDSMALLCAP | -0.5% | -2.6% | 45.6% |
| NSE Indices | 1W | 1M | 1Y |
|---|---|---|---|
| NIFTY SMALLCAP250 | 0.7% | -1.8% | 46.8% |
| NIFTY MID SMALL400 | -0.3% | -2.2% | 44.6% |
| NIFTY500 MULTICAP 50:25:25 | -0.6% | -2.3% | 37.8% |
| NIFTY 500 | -0.9% | -2.5% | 34.2% |
You may also like the below Video Courses
FAQ about CAPLIN POINT LABORATORIES Financials
How the annual revenues of CAPLIN POINT LABORATORIES have changed ?
The Revenues of CAPLIN POINT LABORATORIES have increased by 15.54% YoY .
How the Earnings per Share (EPS) of CAPLIN POINT LABORATORIES have changed?
The Earnings Per Share (EPS) of CAPLIN POINT LABORATORIES has increased by 21.40 % YoY .
Check out Intrinsic Value of Peers of CAPLIN POINT LABORATORIES
Compare Stock Analytics of Peers of CAPLIN POINT LABORATORIES
SUN PHARMACEUTICAL INDUSTRIES LTD vs CIPLA LTD vs DR REDDYS LABORATORIES LTD
ZYDUS LIFESCIENCES LTD vs DIVIS LABORATORIES LTD vs
SUN PHARMACEUTICAL INDUSTRIES LTD vs CIPLA LTD vs DR REDDYS LABORATORIES LTD
ZYDUS LIFESCIENCES LTD vs DIVIS LABORATORIES LTD vs
